Drugs / LUTETIUM TEZUVOTIDEXETAN
LUTETIUM TEZUVOTIDEXETAN
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06516510 | Oct 2024 → Aug 2025 | metastatic prostate carcinoma | Blue Earth Therapeutics Ltd | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06066437 | Mar 2024 → Dec 2026 expected | prostate cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05413850 | Jul 2022 → Aug 2026 overdue | castration-resistant prostate carcinoma | Blue Earth Therapeutics Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-07 | Blue Earth Therapeutics Ltd | Results Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose Intensification of Lutetium (177Lu) rhPSMA-10.1 Injection in mCRPC blueearththerapeutics.com ↗ |
| 2025-06-25 | Blue Earth Therapeutics Ltd | Results Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial blueearththerapeutics.com ↗
Blue Earth Therapeutics today announced radiation dosimetry results for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. |
| 2024-10-08 | Blue Earth Therapeutics Ltd | Results Blue Earth Therapeutics Advances Clinical Development of Lutetium (177Lu) rhPSMA-10.1 Injection with Promising Phase 1 Data blueearththerapeutics.com ↗
Early data from the trial suggests an encouraging safety profile. |
All press releases naming this drug 6 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUTETIUM TEZUVOTIDEXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | 177Lu rhPSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06066437 ↗ |
| Known as | Luteci0 (177lu) tezuvotida tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | Lutecium (177lu) tezuvotide tetraxetan | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | lutetium (177Lu) rhPSMA 10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06516510 ↗ |
| Known as | LUTETIUM (177LU) TEZUVOTIDE TETRAXETAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Known as | Rhpsma-10.1 lutetium lu-177 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068768 ↗ |
| Modality | Other / unclassified | “the radiohybrid (177)Lu-rhPSMA-10.1” PMID 38164586 ↗ Mar 2024 |